Retatrutide
WellnessAlso known as: LY3437943, Reta
Emerging ResearchWhat is Retatrutide?
A triple hormone receptor agonist (GLP-1/GIP/glucagon) developed by Eli Lilly, representing the next generation of obesity treatments beyond semaglutide and tirzepatide. Phase II trials showed unprecedented weight loss of up to 24% of body weight, generating massive interest.
How it works
Simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying), GIP (enhances insulin secretion, may improve fat metabolism), and glucagon (increases energy expenditure, promotes fat oxidation in the liver). The triple mechanism is thought to produce greater weight loss than dual or single agonists.
What marketers claim
- ▸the most powerful weight loss drug ever made
- ▸will replace semaglutide entirely
- ▸no side effects compared to GLP-1 drugs
- ▸cures obesity permanently
What evidence supports
- ✓phase II trial showed up to 24.2% body weight loss at 48 weeks at the highest dose
- ✓dose-dependent weight loss exceeding that seen in tirzepatide phase II trials
- ✓improvements in metabolic markers including HbA1c, triglycerides, and liver fat
- ✓glucagon component may provide additional liver fat reduction and energy expenditure
Research evidence
Key studies on Retatrutide, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Retatrutide once weekly for treatment of obesity (TRIUMPH-2 Phase II)
Finding: At the highest dose (12mg), participants lost an average of 24.2% body weight at 48 weeks. All dose levels produced significantly greater weight loss than placebo.
Limitation: Phase II trial — smaller sample size and shorter duration than typical phase III trials required for approval. Long-term safety and durability of weight loss are unknown.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1-4
Dose escalation phase. Appetite reduction and nausea are common. Weight loss begins, typically 2-4% of body weight in the first month.
Month 2-3
GI side effects often improve as the body adjusts. Weight loss accelerates. Metabolic markers begin improving.
Month 6-9
In phase II trials, participants reached approximately 17-22% weight loss at these timepoints depending on dose.
Month 12+
Weight loss approaches plateau. The 24.2% maximum was observed at 48 weeks. Ongoing use is likely needed to maintain weight loss.
Safety notes & concerns
Full safety guide →- ⚠still in clinical development — not yet FDA approved
- ⚠only phase II data available; phase III trials are ongoing
- ⚠gastrointestinal side effects (nausea, diarrhea, vomiting) are common, especially during dose escalation
- ⚠long-term cardiovascular and safety data are not yet available
- ⚠weight regain after discontinuation is expected based on GLP-1 class data
- ⚠black market versions are already circulating with unknown contents
Pairs well with
Use caution with
Frequently asked questions
How is Retatrutide different from semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) targets only GLP-1. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP. Retatrutide adds a third target — glucagon receptors — which increases energy expenditure and fat oxidation. Each generation has shown incrementally greater weight loss in clinical trials.
When will Retatrutide be available?
Eli Lilly is conducting phase III trials. If results are positive, FDA approval could come in 2026-2027, though timelines are uncertain. It is not currently available through any legitimate clinical channel outside of clinical trials.
Is it safe to buy Retatrutide online now?
No. Any product sold as retatrutide outside of clinical trials is unregulated and may contain incorrect doses, contaminants, or entirely different substances. There is no way to verify the contents of black market peptides. Wait for the approved pharmaceutical product.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Retatrutide
Last updated: 2025-04-09
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.